These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 21736681)

  • 1. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients.
    Malär R; Sjöö F; Rentsch K; Hassan M; Güngör T
    Pediatr Transplant; 2011 Sep; 15(6):580-8. PubMed ID: 21736681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
    Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.
    Lee JW; Kang HJ; Lee SH; Yu KS; Kim NH; Yuk YJ; Jang MK; Han EJ; Kim H; Song SH; Park KD; Shin HY; Jang IJ; Ahn HS
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):944-50. PubMed ID: 22155501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
    Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
    Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children.
    Tesfaye H; Branova R; Klapkova E; Prusa R; Janeckova D; Riha P; Sedlacek P; Keslova P; Malis J
    Ann Transplant; 2014 May; 19():214-24. PubMed ID: 24811685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
    Kletzel M; Jacobsohn D; Duerst R
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):472-9. PubMed ID: 16545731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation.
    Wall DA; Chan KW; Nieder ML; Hayashi RJ; Yeager AM; Kadota R; Przepiorka D; Mezzi K; Kletzel M;
    Pediatr Blood Cancer; 2010 Feb; 54(2):291-8. PubMed ID: 19743300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Busulfan dosing in children with BMIs ≥ 85% undergoing HSCT: a new optimal strategy.
    Browning B; Thormann K; Donaldson A; Halverson T; Shinkle M; Kletzel M
    Biol Blood Marrow Transplant; 2011 Sep; 17(9):1383-8. PubMed ID: 21288495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
    Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan.
    Fisher VL; Barnes YJ; Nuss SL
    Oncol Nurs Forum; 2006 Nov; 33(2):E36-43. PubMed ID: 16518436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.
    Vassal G; Michel G; Espérou H; Gentet JC; Valteau-Couanet D; Doz F; Mechinaud F; Galambrun C; Neven B; Zouabi H; Nguyen L; Puozzo C
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):113-23. PubMed ID: 17393167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
    Zwaveling J; den Hartigh J; Lankester AC; Guchelaar HJ; Egeler RM; Bredius RG
    Anticancer Drugs; 2006 Oct; 17(9):1099-105. PubMed ID: 17001185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
    Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
    Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.
    Kangarloo SB; Naveed F; Ng ES; Chaudhry MA; Wu J; Bahlis NJ; Brown CB; Daly A; Duggan P; Geddes M; Quinlan D; Savoie ML; Shafey M; Stewart DA; Storek J; Yang M; Zacarias N; Yue P; Magliocco AM; Russell JA
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):295-301. PubMed ID: 21801704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
    Nguyen L; Leger F; Lennon S; Puozzo C
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):191-8. PubMed ID: 16133536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
    Williams CB; Day SD; Reed MD; Copelan EA; Bechtel T; Leather HL; Wingard JR; Abbott BL; Abhyankar S; McGuirk JP
    Biol Blood Marrow Transplant; 2004 Sep; 10(9):614-23. PubMed ID: 15319773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.
    Nguyen L; Fuller D; Lennon S; Leger F; Puozzo C
    Bone Marrow Transplant; 2004 May; 33(10):979-87. PubMed ID: 15064687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning.
    Zao JH; Schechter T; Liu WJ; Gerges S; Gassas A; Egeler RM; Grunebaum E; Dupuis LL
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1471-8. PubMed ID: 25977229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.
    Zwaveling J; Bredius RG; Cremers SC; Ball LM; Lankester AC; Teepe-Twiss IM; Egeler RM; den Hartigh J; Vossen JM
    Bone Marrow Transplant; 2005 Jan; 35(1):17-23. PubMed ID: 15502853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.
    McPherson ME; Hutcherson D; Olson E; Haight AE; Horan J; Chiang KY
    Bone Marrow Transplant; 2011 Jan; 46(1):27-33. PubMed ID: 20305698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.